Retatrutide 24mg

Description

Strength: 24mg
CAS: 2381089-83-2
Chemical Formula: C₂₂₁H₃₄₂N₄₆O₆₈
Molecular weight: 4731.33 g/mol
Peptide Sequence: Tyr-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{α-Me-Leu}-Leu-Asp-Lys-{diacid-C20-gamma-Glu-(AEEA)-Lys}-Ala-Gln-{Aib}-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 (Sodium salt)
Synonyms: Retatrutide acetate, LY3437943
Storage: Store 2–8 °C (≤–20 °C long-term). RT exposure during transport acceptable. Protect from light.
Shelf life: 24 months from the manufacturing date.

The retatrutide peptide is an investigational, long-acting synthetic peptide originally developed by Eli Lilly and currently undergoing Phase 3 clinical evaluation. It is classified as a triple-agonist due to its simultaneous activation of GLP-1, GIP, and glucagon receptors, making it a compound of interest in metabolic and cardiometabolic research.

Retatrutide (LY3437943) consists of a single chain of 39 amino acids and is chemically modified with a fatty diacid moiety to enhance albumin binding and reduce renal clearance. It has been investigated for effects on body weight regulation, glucose metabolism, insulin sensitivity, liver fat, and energy expenditure in controlled research settings. The product is supplied as a lyophilized powder in sterile, sealed vials for laboratory research use only.

Retatrutide is a next-generation compound for metabolic research. While outcomes have been reported in clinical trials, it remains investigational and is not approved for therapeutic use.

• Triple-Agonist Activity: Targets GLP-1, GIP, and glucagon receptors
• Extended Half-Life: Approximately 6 days, supporting once-weekly dosing protocols in research settings.
• High Purity & Stability: Supplied as pharmaceutical-grade lyophilized peptide.
• Primary Research Areas: Obesity, type 2 diabetes, insulin resistance, and metabolic dysfunction.
• Clinical Data Reference: Phase 2 trials evaluated doses up to 12 mg, with mean weight loss reported up to 2%.
• Storage Integrity: Requires refrigerated or frozen storage to preserve molecular stability.
• Regulatory Status: Investigational compound with no FDA approval.

Retatrutide exerts its effects through coordinated activation of three metabolic hormone receptors:

• GLP-1 receptor activation supports appetite suppression, delayed gastric emptying, and improved glycemic control.
• GIP receptor activation enhances glucose-dependent insulin secretion and insulin sensitivity.
• Glucagon receptor activation may increase resting energy expenditure and influence lipid metabolism.

This multi-receptor mechanism is being investigated for its role in weight reduction, metabolic efficiency, liver fat modulation, and cardiometabolic risk endpoints in controlled research models.

Published Phase 2 clinical research evaluated retatrutide at once-weekly doses up to 12 mg over a 48-week period. The 24 mg vial format represents a research-supply configuration only and does not indicate a recommended single dose. No published human clinical trial has evaluated doses exceeding 12 mg weekly in the available literature.

Reported research observations include:

• Significant body weight reduction
• Improved insulin sensitivity and glucose control
• Substantial decreases in hepatic fat content
• Mild, transient increases in resting heart rate (5–10 bpm)

No safe or approved dosage has been established for human use outside regulated clinical trials.

• Store lyophilized peptide at 2–8 °C, protected from light and moisture.
• For long-term storage, unopened vials may be kept at –20 °C to –80 °C.
• Once reconstituted, refrigerate and do not refreeze. Avoid repeated freeze–thaw cycles.

Researchers seeking to order retratrutide peptide must follow all institutional and regulatory requirements.

References

https://pubmed.ncbi.nlm.nih.gov/37366315/

https://pubmed.ncbi.nlm.nih.gov/37385280/

https://pubmed.ncbi.nlm.nih.gov/38858523/

https://pubmed.ncbi.nlm.nih.gov/36354040/

Compliance Notice

This product is intended for laboratory research use only and is not approved for human or veterinary use.